Program
HRS-1893
A development code. Also written as “HRS-1893 Tablet”, “Test formulation of HRS-1893 tablet” and “Reference formulation of HRS-1893 tablet”.
In Jiangsu HengRui Medicine's pipeline, Myosin
. Its studies are mostly in Cardiomyopathy, Hypertrophic · Cardiomyopathies · Heart Failure, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 125 open or running | phase 3since Jun 6, 2025 | May 18, 2023 | Mar 2027phase 2 · NCT07269717 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-1893
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 18, 2023First study: phase 1 study in Cardiomyopathy, HypertrophicFirst studyNCT05879523 · 76 enrolled · China
- Apr 3, 2024Phase 1 study in Cardiomyopathy, HypertrophicNCT06354556 · 14 enrolled · China
- Jun 28, 2024Phase 2 study in Cardiomyopathy, HypertrophicNCT06516068 · 42 enrolled · China
- Jan 9, 2025Phase 1 study in Cardiomyopathy, HypertrophicNCT06775834 · 24 enrolled · China
- Feb 4, 2025Phase 2 study in Non-obstructive Hypertrophic CardiomyopathyNCT06816251 · 84 enrolled · China
- May 20, 2025Early phase 1 study in Cardiomyopathy, HypertrophicNCT07033455 · 20 enrolled · Australia
- Jun 6, 2025Phase 3 study in Cardiomyopathy, HypertrophicNCT07021976 · 228 enrolled · China
- Jun 6, 2025Phase 2 study in Cardiomyopathy, HypertrophicNCT07021963 · 300 planned · China
- Nov 26, 2025Phase 1 study in CardiomyopathiesNCT07272330 · 38 enrolled · China
- Nov 26, 2025Phase 2 study in Heart Failure With Preserved Ejection FractionNCT07269717 · 48 planned · China
- Mar 11, 2026Phase 1 study in CardiomyopathiesNCT07479641 · 58 enrolled · China
- Jun 15, 2026Phase 1 study in CardiomyopathiesNCT07656779 · 6 planned · China
Ahead
- Mar 2027Primary completion: phase 2 study in Heart Failure With Preserved Ejection FractionNCT07269717
- Dec 2027Primary completion: phase 2 study in Cardiomyopathy, HypertrophicNCT07021963
TargetBeta
“Myosin”the company's pipeline, read by Claude · source
Other programs on MYH7
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mavacamtenrule | Bristol-Myers Squibb | phase 4 | 20 |
| omecamtiv mecarbilrule | Cytokinetics | phase 3 | 16 |
| danicamtivrule | Bristol-Myers Squibb | phase 3 | 7 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07656779Cardiomyopathies · China | 1 | Not yet recruiting | Jul 2026 | 6 |
| NCT07479641Cardiomyopathies · China | 1 | Completed | Sep 14, 2026 | 58 |
| NCT07272330Cardiomyopathies · China | 1 | Completed | Mar 21, 2026 | 38 |
| NCT07269717Heart Failure With Preserved Ejection Fraction · China | 2 | Recruiting | Mar 2027 | 48 |
| NCT07021976Cardiomyopathy, Hypertrophic · China | 3 | Active, not recruiting | Sep 2026 | 228 |
| NCT07021963Cardiomyopathy, Hypertrophic · China | 2 | Recruiting | Dec 2027 | 300 |
| NCT07033455Cardiomyopathy, Hypertrophic · Australia | Early 1 | Completed | Sep 5, 2025 | 20 |
| NCT06816251Non-obstructive Hypertrophic Cardiomyopathy · China | 2 | Completed | Nov 18, 2025 | 84 |
| NCT06775834Cardiomyopathy, Hypertrophic · China | 1 | Completed | Jul 23, 2025 | 24 |
| NCT06516068Cardiomyopathy, Hypertrophic · China | 2 | Active, not recruiting | Nov 18, 2024 | 42 |
| NCT06354556Cardiomyopathy, Hypertrophic · China | 1 | Completed | May 20, 2024 | 14 |
| NCT05879523Cardiomyopathy, Hypertrophic · China | 1 | Completed | Mar 21, 2024 | 76 |
How it is read
Names in the registry
- “HRS-1893”, 5 entries
- “HRS-1893 Tablet”, 2 entries
- “Test formulation of HRS-1893 tablet”, 1 entry
- “Reference formulation of HRS-1893 tablet”, 1 entry
- “HRS-1893 Tablets”, 1 entry
Codes read as this program: HRS1893.
Conditions, from the studies’ own filings
- Cardiomyopathy, Hypertrophic, 8 studies
- Cardiomyopathies, 3 studies
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.